CoChat

Stem cell therapy for Alzheimer’s disease and related disorders: current status and future perspectives

Open access
Tong, Leslie M, Fong, Helen, Huang, Yadong · 2015 · Experimental & Molecular Medicine
Cited by 83

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Underlying cognitive declines in Alzheimer’s disease (AD) are the result of neuron and neuronal process losses due to a wide range of factors. To date, all efforts to develop therapies that target specific AD-related pathways have failed in late-stage human trials. As a result, an emerging consensus in the field is that treatment of AD patients with currently available drug candidates might come too late, likely as a result of significant neuronal loss in the brain. In this regard, cell-replacement therapies, such as human embryonic stem cell- or induced pluripotent stem cell-derived neural cells, hold potential for treating AD patients. With the advent of stem cell technologies and the ability to transform these cells into different types of central nervous system neurons and glial cells, some success in stem cell therapy has been reported in animal models of AD. However, many more steps remain before stem cell therapies will be clinically feasible for AD and related disorders in humans. In this review, we will discuss current research advances in AD pathogenesis and stem cell technologies; additionally, the potential challenges and strategies for using cell-based therapies for AD and related disorders will be discussed. Stem cell therapies could help promote brain regeneration and recovery in people with Alzheimer's disease and related disorders. In a review article, Yadong Huang and colleagues from the Gladstone Institute of Neurological Disease at the University of California, San Francisco, USA, discuss the various stem cell strategies that researchers are now considering for treating Alzheimer's disease. Using embryonic or reprogrammed stem cells, some groups are trying to derive nerve cells that can replace those cells destroyed by the disease. Others want to use stem cells to deliver factors that can either protect nerve tissues or clear away the amyloid plaques that clog the brains of patients affected by Alzheimer's disease. Preclinical studies in rodent models have shown some success, but much more research is needed before clinical trials can begin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/emm.2014.124

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 83

Metadata

Authors
Tong, L. M., Fong, H., & Huang, Y.
Venue
Experimental & Molecular Medicine
Published
2015-03-13
Volume
47
Issue
3
Pages
e151-e151
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W2090289365
Cited by
83
References
35
FWCI
8.61
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.